Interstitial cystitis/painful bladder syndrome (IC/PBS) is a poorly understood chronic
disorder of unknown etiology consisting of irritative bladder symptoms and pelvic pain that
dramatically affects quality of life.
Preclinical study data (obtained by using an IC/PBS model in Sprague-Dawley female rats) have
demonstrated normalization of urinary frequency indicating that LP may be a potent protectant
of the bladder mucosa against inflammation and irritation. Intravesical LP has so far
demonstrated an excellent safety profile and minimal toxicity at concentrations of 2 mg/ml.
Thus, we hypothesize that intravesical instillation of LP may form a molecular film on
bladder ulcer surfaces in patients with IC and provide a safe, effective, and minimally
invasive treatment option to alleviating symptoms.